- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- DR. REDDYS LAB
DR. REDDYS LAB Share Price 
(REDY)
Here is the latest stock price and chart of Dr. Reddys. For more details, see the Dr. Reddys company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Jul 19, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)2,030.90 | Open (Rs) 2,088.00 | High (Rs) 2,088.00 | Low (Rs) 2,027.10 |
| % Change-1.65 | Volume 60,502 | Value (Rs) 123,939,977 | 52-Week H/L 2,788.00 / 1,888.00 |
| Live NSE Quotes | Jul 19, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)2,029.20 | Open (Rs) 2,077.80 | High (Rs) 2,077.80 | Low (Rs) 2,025.00 |
| % Change-1.76 | Volume 762,721 | Value (Rs) 1,562,559,079 | 52-Week H/L 2,787.00 / 1,887.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 56.62 | P/E Ratio (x) 35.87 | Market Cap (Rs m) 336,540.44 | P/BV (x) 2.68 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
DR. REDDYS LAB Share Price Today:
DR. REDDYS LAB last traded price was down 1.7% to Rs 2,030.9 on the BSE. On the NSE, DR. REDDYS LAB last traded price was down 1.8% to Rs 2,029.2. The total volume of shares traded was 0.8 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.3%. And the benchmark S&P BSE SENSEX was at 36,351.2 (down 0.1%).
Over the last 30 days, the DR. REDDYS LAB share price is down 15.2%. And over the last one year, DR. REDDYS LAB share price is down 26.7%.
|
| |
Today's Market
Sensex Ends Volatile Day Flat; Pharma Stocks Top Losers(Closing)
After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day flat.
Related Views On News
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)
Nov 13, 2017Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.
Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)
Aug 8, 2017Profits plunge due to higher raw material costs.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
More Views on NewsMost Popular
How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)
Jul 12, 2018Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.
The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)
Jul 10, 2018If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...
The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)
Jul 11, 2018The price signals that MSP sends out, creates its own set of problems.
New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)
Jul 6, 2018ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.
When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)
Jul 6, 2018Buy Companies that can fight all kinds of Pandas and Bears in the long run.
MoreTRACK DR. REDDYS LAB
- Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. REDDYS LAB
DR. REDDYS LAB - DISHMAN PHARMA COMPARISON
COMPARE DR. REDDYS LAB WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.